Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Sarsia is an early-stage venture capital firm founded in 2003 and based in Bergen, Norway. The firm focuses on investing in technologies and companies that contribute to a greener and healthier future. Sarsia bridges government-backed capital and private investment to support deep tech founders at the earliest stages, emphasizing the importance of competence and capital in transforming laboratory results into effective treatments.
As of now, Sarsia manages approximately €90 million across its investment vehicles, with a fund size of $50 million for its latest fund. The firm has a portfolio of 33 companies, showcasing its commitment to fostering innovation in various sectors. Sarsia's notable milestones include successful exits with companies like BergenBio and Vaccibody, highlighting its effectiveness in identifying and nurturing high-potential startups.
Sarsia primarily invests in two sectors: Life Sciences and Technology, Energy, and Sustainability. In Life Sciences, the firm targets unmet medical needs, focusing on companies that pioneer new approaches in medicine. This includes investments in clinical-stage companies like Calluna Pharma, which is developing treatments for immunological diseases.
In the Technology, Energy, and Sustainability sector, Sarsia seeks technologies and founders that can accelerate the green transition and build sustainable companies. The firm is particularly interested in innovations that optimize energy efficiency, such as Cetasol, which enhances energy efficiency for ships using AI. Sarsia typically invests at the pre-seed, seed, and Series A stages, with check sizes ranging from NOK 5 million to NOK 20 million (approximately €430,000 to €1.7 million).
Sarsia's portfolio includes a diverse range of companies focused on biotechnology, healthcare, and clean energy. Notable companies include:
These companies exemplify Sarsia's commitment to investing in technologies that address unmet medical needs and promote sustainability.
Sveinung Hole: Managing Partner with extensive experience in venture capital and a background in technology investments.
Marit Wick: Partner and CFO, responsible for financial strategy and operations, with a strong background in finance.
Øivind Enger: Partner specializing in Life Sciences, with a focus on biotech investments and a history of successful deal-making.
Jon Trygve Berg: Partner focused on Technology, Energy, and Sustainability, bringing expertise in clean technology investments.
Farzad Abdi-Dezfuli: Partner in Life Sciences, known for his work in clinical-stage investments and healthcare innovation.
Hilde Holdhus: Partner specializing in Technology, Energy, and Sustainability, with a strong track record in energy-efficient technologies.
Jon-Kåre Hansen: Partner focused on Technology, Energy, and Sustainability, with expertise in sustainable business models.
Henrik Solberg-Johansen: Partner specializing in Technology, Energy, and Sustainability, known for his work in renewable energy investments.
Erlend Skagseth: Senior Partner with a broad background in venture capital and strategic investments.
Maija Slaidiņa: Investment Manager in Life Sciences, focusing on early-stage biotech companies.
Olav Skjervheim: Compliance officer ensuring regulatory adherence and operational integrity.
To pitch Sarsia, founders should visit the firm's website at sarsia.com. It is recommended to include a comprehensive deck that outlines the business model, market analysis, and technology details. Sarsia prefers pitches that are clear and concise, highlighting the potential impact of the startup's innovations. Response times may vary, but founders should expect to hear back within a few weeks.
In 2024, Sarsia participated in a NOK 260 million funding round for Heimdal Power, showcasing its active involvement in the clean energy sector. The firm also invested in additional funding rounds for Vestland Pharma and Calluna Pharma, further solidifying its commitment to supporting innovative healthcare solutions.
Recent updates indicate that Sarsia has made three investments in 2025 and five in 2024, demonstrating a consistent pace of deal activity. The firm continues to focus on its core sectors, emphasizing its role in the Norwegian innovation ecosystem.
What are Sarsia's investment criteria?
Sarsia invests in early-stage companies primarily in the Life Sciences and Technology, Energy, and Sustainability sectors. The firm looks for technologies that address unmet medical needs and promote sustainability.
How can I pitch to Sarsia?
Founders can pitch their ideas through Sarsia's website at sarsia.com. It is advisable to include a clear business model, market analysis, and details on the technology or product being developed.
What makes Sarsia different from other VCs?
Sarsia bridges government-backed capital and private investment, providing unique access to funding opportunities. The firm emphasizes strategic guidance and support in navigating the complexities of scaling innovative technologies.
What is Sarsia's geographic focus?
Sarsia primarily focuses on investments within Europe, particularly in Norway, where it aims to support the local innovation ecosystem.
What is the typical check size for investments?
Sarsia typically invests between NOK 5 million and NOK 20 million (approximately €430,000 to €1.7 million) in its portfolio companies.
What kind of post-investment support does Sarsia provide?
Sarsia offers access to a network of industry experts, strategic guidance, and assistance in navigating the complexities of scaling innovative technologies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.